Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

61.46
-0.9400-1.51%
Post-market: 61.680.2214+0.36%19:59 EDT
Volume:10.77M
Turnover:663.45M
Market Cap:125.12B
PE:13.53
High:62.61
Open:62.20
Low:61.25
Close:62.40
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.76
T/O Rate:0.53%
Dividend:2.51
Dividend Rate:4.08%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.61
PE(LYR):17.76

Loading ...

Bristol-Myers Squibb Moves Into Depression Market With New Phase 2 Trial

TIPRANKS
·
Sep 05

Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects

Dow Jones
·
Sep 04

Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns

MT Newswires Live
·
Sep 04

Dow Jones Top Company Headlines at 11 PM ET: the 'Deeply Nerdy' Founders Behind Nvidia's $13 Billion Bet on Hugging Face | Musk's ...

Dow Jones
·
Sep 04

Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer

Reuters
·
Sep 03

Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services

Dow Jones
·
Sep 03

Bristol Myers Squibb Co. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 03

London Midcaps Lead Losses as Rising Gilt Yields Weigh; Reckitt Gains

Reuters
·
Sep 02

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

Oxford BioMedica Slides as Novartis, Bristol-Myers Squibb Pause CAR-T Autoimmune Trials

Reuters
·
Sep 01

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

Bristol-Myers Squibb Spokesperson - Implemented a Voluntary Pause to Review Clinical Data Across Our Zola-Cel Program

THOMSON REUTERS
·
Sep 01

Rpt: Bristol-Myers Squibb Also Pauses Similar Trials as a Precautionary Measure- WSJ

THOMSON REUTERS
·
Sep 01

Novartis Pauses Autoimmune Cell Therapy Studies After Deaths

Dow Jones
·
Sep 01

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Aug 31

Bristol Myers presents results for EXPLORER-LTE cohort of MAVA-LTE study

TIPRANKS
·
Aug 31

Procter & Gamble, Target, Canopy, Bristol, Oklo Insider Shock

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Sweden's Elicera Therapeutics Q2 Loss Widens

Reuters
·
Aug 28

Bristol-Myers Squibb Extends Deucravacitinib Program, Signaling Long-Term Autoimmune Ambitions

TIPRANKS
·
Aug 28